drugset / Trial / NCT05027919
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
Phase 2
Recruiting
60 enrolled
University of Maryland, Baltimore
National Institute on Drug Abuse (NIDA) · collab
RandomizedSingle-groupOpen-labelBasic science
Summary
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2026-11-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lofexidine | Small molecule | — | Oral |
| Background | Hydromorphone | Other / unclassified | 120 mg | Oral |
| Background | Naloxone | Small molecule | 0.2 mg | Intramuscular |
| Background | Naloxone | Small molecule | 0.4 mg | Intramuscular |